[Enhanced antitumor action of 5-fluorouracil when used in combination with 4-methylmercaptopyrazolo[3,4-d]pyrimidine 1-nucleoside].
Mice BDF1 with L 1210 or mice BALB/c with plasmacytoma MOPS-406 after pretreatment with ineffective doses of 1-beta-D-ribofuranosyl-4-methylmercaptopyrazolo(3,4-d)pyramidin e (25 to 100 mg/kg per 5 days) were treated with 5-fluorouracil at the optimal dose 100 mg per day. This combination produced a 1.5-2-fold or 2 to 4 fold enhancement of the antitumour effect of 5-fluorouracil without simultaneous increase of lethal toxicity.